Latest News for: pd-l1
Edit
Jupiter DAO Backs Net Zero Emissions Plan With 75% Vote, Postpones Jupuary And Halts New Supply
NULLTX 22 Feb 2026
JupiterExchange community members have concluded a closely watched governance vote, with a decisive 75% majority backing the “Net Zero Emissions” proposal ... New ... pic.twitter.com/zcrQjS3jga. — SolanaFloor (@SolanaFloor) February 22, 2026 ... Disclosure.
Edit
US military assets in the Middle East
The New Arab 21 Feb 2026
The USS Gerald R. Ford aircraft carrier entered the Mediterranean Sea on Friday, further boosting American firepower in a region that has seen a massive military buildup ahead of potential strikes against Iran ... Ships ... Aircraft ... Air defenses ... ....
Edit
Despite illness, Tyler Tanner galvanizes Vanderbilt basketball almost to win
Columbia Daily Herald 19 Feb 2026
Edit
PD-1 and PD-L1 Inhibitors Competitive Landscape Report 2026: Comprehensive Insights on 200+ Drugs from Over ...
Nasdaq Globe Newswire 18 Feb 2026
The PD-1 and PD-L1 inhibitors market offers significant opportunities by expanding cancer treatment options using immunotherapy.
Edit
PD-1/PD-L1 Checkpoint Inhibitors Market Research and Global Forecast Report 2026-2032
Nasdaq Globe Newswire 17 Feb 2026
The PD-1/PD-L1 market offers opportunities in therapy combinations, real-world data use, and digital patient support ...
Edit
Hastings Tribune
12 Feb 2026
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or ...
Hastings Tribune
12 Feb 2026
Edit
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC) (Agilent Technologies Inc)
Public Technologies 11 Feb 2026
Edit
Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers
PR Newswire 10 Feb 2026
The grant of a patent will build upon Genprex's existing intellectual property foundation, which includes granted patents for the use of REQORSA in combination with PD-L1 antibodies in the U.S.
Edit
Leads Biolabs’ PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Dosed First Patient in New Indication, Paving a ...
GetNews 10 Feb 2026
Edit
BWXT opens Melbourne IT center, pursues moon nuclear reactor for NASA
The Palm Beach Post 06 Feb 2026
A Fortune 1000 company that produces nuclear reactors and uranium fuel for the U.S ... NASA and the U.S. Department of Energy aim to deploy a nuclear reactor to the moon's surface by 2030. BWXT is considered a prime candidate ... You just can't ... 1 in Melbourne.
Edit
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
PR Newswire 30 Jan 2026
What differentiates NDL2 is that we are applying protein degradation to PD-L1 as one of the most clinically validated targets in cancer, while addressing a resistance mechanism not reached by existing ...
Edit
Leads Biolabs’ PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Earns EU Orphan Drug Designation—Potential First-in-Class Therapy to ...
GetNews 23 Jan 2026
Opamtistomig (LBL-024) is a potential first-in-class bispecific antibody that simultaneously targets PD-L1 and the co-stimulatory receptor 4-1BB ... for PD-L1 and 4-1BB with an optimized affinity ratio.
- 1
- 2
- Next page »